Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma
About This Grant
PROJECT SUMMARY / ABSTRACT Malignant pleural mesothelioma (MPM) presents a significant challenge in oncology due to its rarity, lethality, and heterogeneity. This complexity necessitates the development of innovative therapeutic strategies, particularly in light of the partial effectiveness and resistance issues associated with current immune checkpoint inhibitors (ICIs). Our research addresses these challenges by focusing on the identification and validation of liquid biomarkers to enable personalized treatment strategies and improve patient outcomes in MPM. Recent advancements in ICIs have offered new hope, with monotherapy showing about a 20% objective response rate, which can be significantly improved with combination therapies. However, resistance to these treatments remains a substantial barrier, affecting approximately two-thirds of MPM patients. We have identified key prognostic factors such as tumor PD-L1 expression, which is associated with unfavorable survival after conventional treatment without ICIs, and the beneficial impact of tertiary lymphoid structures, immune triads, intact 9p21.3 loci, and low soluble mesothelin-related peptide (SMRP) levels on ICI response. We propose a dual-aim research strategy to address the urgent need for precise biomarkers in MPM treatment. Aim 1 focuses on validating the combined utility of MHC genotype and SMRP levels to stratify patient survival and monitor disease progression, employing a predictive model validated through a cohort of over 400 MPM patients. Aim 2 seeks to elucidate the mechanistic connections between liquid multiomics profiles and the tumor immune landscape, using state-of-the-art technologies to identify and verify novel biomarkers and therapeutic targets. This integrative analysis of immune genotyping and circulating proteins aims to accurately map the tumor immune landscape, guiding the development of biomarker-driven therapeutic strategies. By leveraging liquid multiomics for molecular profiling, our project stands to significantly deepen the understanding of MPM biology, identify clinical-grade liquid biomarkers for treatment response prediction, and advance precision oncology. Our multidisciplinary team, with expertise spanning basic to translational research and advanced immunology, is uniquely positioned to make impactful contributions to precision cancer therapy for MPM. This research promises not only to enhance the precision and efficacy of MPM care but also to set new standards in the management of this challenging disease, marking a significant step forward in the pursuit of personalized oncology solutions.
Grant Summary
Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma is a NCI - National Cancer Institute grant providing up to $664K for university, nonprofit, healthcare org. Applications are due 2031-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $664K
2031-07-31
- 1Confirm your organization is eligible for Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma: Frequently Asked Questions
Who is eligible for the Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma?
Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma provide?
Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma provides up to $664K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma deadline?
Applications for Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma are due 2031-07-31 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma?
To apply for Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.